Your browser doesn't support javascript.
loading
Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry Perspective.
Kellie, John F; Tran, John C; Jian, Wenying; Jones, Barry; Mehl, John T; Ge, Ying; Henion, Jack; Bateman, Kevin P.
Afiliação
  • Kellie JF; Bioanalysis, Immunogenicity & Biomarkers, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States.
  • Tran JC; Biochemical & Cellular Pharmacology, Genentech Inc., South San Francisco, California 94080, United States.
  • Jian W; DMPK, Janssen Research & Development, Johnson & Johnson, Spring House, Pennsylvania 19477, United States.
  • Jones B; Q Squared Solutions, 19 Brown Road, Ithaca, New York 14850, United States.
  • Mehl JT; Bioanalytical Research, Bristol-Myers Squibb, Princeton, New Jersey 08648, United States.
  • Ge Y; Department of Cell and Regenerative Biology, Department of Chemistry, Human Proteomics Program, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
  • Henion J; Advion, Inc., 61 Brown Road, Ithaca, New York 14850, United States.
  • Bateman KP; PPDM, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
J Am Soc Mass Spectrom ; 32(8): 1886-1900, 2021 Aug 04.
Article em En | MEDLINE | ID: mdl-32869982
ABSTRACT
Recent advancements in immunocapture methods and mass spectrometer technology have enabled intact protein mass spectrometry to be applied for the characterization of antibodies and other large biotherapeutics from in-life studies. Protein molecules have not been traditionally studied by intact mass or screened for catabolites in the same manner as small molecules, but the landscape has changed. Researchers have presented methods that can be applied to the drug discovery and development stages, and others are exploring the possibilities of the new approaches. However, a wide variety of options for assay development exists without clear recommendation on best practice, and data processing workflows may have limitations depending on the vendor. In this perspective, we share experiences and recommendations for current and future application of mass spectrometry for biotherapeutic molecule monitoring from preclinical and clinical studies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espectrometria de Massas / Proteínas Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espectrometria de Massas / Proteínas Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article